Consultant to Develop the Implementation Plan for the Multiple First-line Treatment (MFT) Strategy in Rwanda
Rwanda has made significant progress in reducing the malaria burden over the past decade. However, recent evidence has confirmed the presence of partial artemisinin resistance in Plasmodium falciparum parasites circulating in the country. This development poses a serious threat to the efficacy of existing artemisinin-based combination therapies (ACTs), which are the cornerstone of malaria treatment.
To address this emerging threat and preserve the efficacy of ACTs, the World Health Organization (WHO) recommends the adoption of the Multiple First-line Treatment strategy. MFT involves the simultaneous use of more than one ACT as first-line therapy, distributed across different geographic or demographic segments. This approach aims to reduce drug pressure on any single treatment regimen and delay the further spread of resistance.
In line with this guidance, Jhpiego in collaboration with the Rwanda Biomedical Centre (RBC) is taking steps to develop a nationally tailored MFT implementation plan. This plan will guide the structured and evidence-informed rollout of MFT as part of Rwanda’s malaria control and elimination strategy.
The primary objective of this consultancy is to design a detailed implementation plan for the roll-out of the MFT strategy in Rwanda, aligning with national malaria strategic plan, Jhpiego-supported interventions, and international best practices.
Over a period of 10 working days, the consultant will:
The consultant will be contracted by Jhpiego Rwanda and will report directly to the Jhpiego UNITAID STOP AMDR Project Director , with oversight and technical input from the Rwanda Biomedical Centre (RBC) – Malaria and Other Parasitic Diseases Division.
Qualified candidates should submit:
Submission Deadline: 5 days
Submit Applications To: iCIMS
Software Powered by iCIMS
www.icims.com